One Therapy. The Same Proven Results. Different names

For decades, cerebroprotein hydrolysate has been used in neurology as a neuroprotective and nootropic agent. Most people know it under the brand name Cerebrolysin, produced by Ever Pharma in Austria – this is the original and most widely recognized formulation. However, due to trademark and legal reasons, the same product is sold under different names in various countries. For example, in some markets, it’s available as Renacenz, often at a higher price despite being the same formula. There’s also a Chinese version, though manufacturing standards may differ.

Applications in Practice

Neuroprotection – safeguarding neurons from damage and degeneration.
Neurotrophic Support – stimulating growth, survival, and repair of nerve cells.
Enhanced Synaptic Plasticity – improving communication between neurons.
Cognitive Function Improvement – supporting memory, attention, and learning.
Functional Recovery Promotion – accelerating rehabilitation after brain injury or stroke.
Metabolic Optimization – improving energy metabolism in neural tissue.

Interestingly, in Belarus, a similar product called Cerebrolysate is produced, though it hasn’t gained much popularity globally. Historically, hospitals used large 50 mL vials for neurological treatments, while smaller 1 mL ampoules were made for veterinary use in dogs and cats with CNS injuries.

The primary active peptide in Cerebrolysin is believed to be P21, which has notable neurogenic and neuroprotective effects. Unlike the full cerebrolysin complex, P21 can be administered intranasally, offering a more convenient alternative to injections.

Why Order Cerebroprotein Now

At the end of the day, the name isn’t what matters most – it’s about who makes it and where. What we offer is the authentic, Austrian-made original, ensuring the highest quality.

Always in stock,

same therapeutic value,

competitive price.

Order Cerebroprotein

View Clinical Data

1. Cao, W., et al. (2020). A novel cerebroprotein hydrolysate, CH1, ameliorates chronic focal cerebral ischemia injury by promoting white matter integrity via the Shh/Ptch-1/Gli-1 signaling pathway.
2. Chen, M., et al. (2023). Cerebroprotein hydrolysate attenuates neurodegenerative changes in Alzheimer’s mice model via ferroptosis pathway.
3. Desousa, A., et al. (2014). The use of cerebroprotein hydrolysate in dementia: A case series of 25 cases seen in a tertiary general hospital.
4. Fan, F., et al. (2022). The efficacy and safety of Alzheimer’s disease therapies: An updated umbrella review.
5. Guo, H., et al. (2023). Identification and validation of active ingredient in Cerebrotein Hydrolysate-I based on pharmacokinetic and pharmacodynamic studies.
6. Gupta, P., et al. (2014). Cerebroprotein hydrolysate: Innovation in the treatment of neurodegenerative disorders.
7. Karia, S., et al. (2013). Cerebroprotein hydrolysate in traumatic brain injury.
8. Karia, S., et al. (2021). A retrospective chart analysis of 34 cases with the use of oral cerebroprotein hydrolysate in dementia in a tertiary general hospital.
9. Levin, O., et al. (2019). Depression and cognitive decline in elderly: Causes and consequences.
10. Parveen, N., et al. (2023). A pilot study to evaluate the effects of cerebroprotein hydrolysate on neurological outcomes and hospital stay in patients admitted for ischemic and hemorrhagic stroke.
11. Rui, S., et al. (2019). Administration of troxerutin and cerebroprotein hydrolysate injection alleviates cerebral ischemia/reperfusion injury by down-regulating caspase molecules.
12. Wang, Q., et al. (2024). Efficacy of a combination of troxerutin and cerebroprotein hydrolysate in acute cerebral infarction: Meta-analysis and systematic review.
13. Yang, E., et al. (2024). Neuroprotective effects of cerebroprotein hydrolysate and its combination with antioxidants against oxidative stress-induced HT22 cell death.